Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
LPAR5 encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. Zusätzlich bieten wir Ihnen Lysophosphatidic Acid Receptor 5 Proteine (5) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 32 products:
These results suggest that the cell motile activity is regulated through the induction of LPA5 by phorbol ester and anticancer drug treatments in A375cells.
These results suggest that the diverse roles of LPA4 (zeige LPAR4 Antikörper), LPA5 and LPA6 (zeige LPAR6 Antikörper) are involved in the activation of tumor progression in pancreatic cancer cells.
Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.
MMP-2 (zeige MMP2 Antikörper) and MMP-9 (zeige MMP9 Antikörper) were found in HT1080L5 cells, in comparison with control cells. These results suggest that LPA (zeige APOA Antikörper) signaling via LPA5 negatively regulates the cell motile and invasive activities of human sarcoma cells.
These results suggest that LPA5 may act as a negative regulator of cellular responses in mouse fibroblast 3T3 cells, similar to the case for LPA1 (zeige LPAR1 Antikörper).
It was shown that lysophosphatidic acid 5 receptor transactivated the epidermal growth factor receptor (zeige EGFR Antikörper) and that inhibition of epidermal growth factor receptor (zeige EGFR Antikörper) blocked lysophosphatidic acid 5 receptor-dependent activation of NHE3 (zeige SLC9A3 Antikörper).
LPA5 is a bona fide LPA (zeige APOA Antikörper) receptor on human mast cells responsible for the majority of LPA (zeige APOA Antikörper) induced MIP-1beta (zeige CCL4 Antikörper) release.
LPA4 (zeige LPAR4 Antikörper) and LPA5 receptors induce osteoblastic differentiation of human mesenchymal stem cells
Data show that CLL cells express LPA (zeige APOA Antikörper) receptors LPA(1 (zeige LPAR1 Antikörper)-5) and VEGF (zeige VEGFA Antikörper) receptors, and the plasma levels of VEGF (zeige VEGFA Antikörper) are elevated in CLL patients.
GPR92 is proposed as a fifth LPA (zeige APOA Antikörper) receptor, LPA5, which likely has distinct physiological functions in view of its expression pattern.
These findings suggest that tumor and stromal LPA receptors, in particular LPA1 (zeige LPAR1 Antikörper) and LPA5, play different roles in invasion and the seeding of metastasis
Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response
These data expand the influences of LPA signaling in neuropathic pain through a second LPA receptor subtype, LPA(5), involving a mechanistically distinct downstream signaling pathway compared with LPA(1 (zeige LPAR1 Antikörper)).
Lysophosphatidic acid (LPA) is a potent stimulant of NHE3 (zeige SLC9A3 Antikörper) and fluid absorption in the intestine, signaling through LPA(5). Regulation by LPA(5) depends on its interaction with NHERF2 (zeige SLC9A3R2 Antikörper).
GPR92 is highly expressed in the lymphocyte compartment of the gastrointestinal tract
Our data indicate that GPR93 can contribute to the observed induction of CCK expression and secretion by peptone and provide evidence that G protein-coupled receptors can transduce dietary luminal signals.
This gene encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. This protein transmits extracellular signals from lysophosphatidic acid to cells through heterotrimeric G proteins and mediates numerous cellular processes. Many G protein receptors serve as targets for pharmaceutical drugs. Transcript variants of this gene have been described.
G protein-coupled receptor 92
, G-protein coupled receptor 92
, G-protein coupled receptor 93
, LPA receptor 5
, lysophosphatidic acid receptor 5
, putative G protein-coupled receptor 92